OneBlood, Inc.June 6, 2025

FDA 483 - OneBlood, Inc. - June 06, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

An FDA inspection of OneBlood, Inc., a blood bank in St Petersburg, FL, revealed a significant and recurrent issue with regulatory compliance. The firm failed to submit 23 out of 282 biological product deviation reports within the mandated 45-day timeframe. This indicates an ongoing problem with timely reporting of critical events.

Company: OneBlood, Inc.
Inspection Date: June 6, 2025
Product Type: Biologics
Office: Florida District Office
People: Laura E. Garcia
Annette Melendez
Steen N. Graham

Open in Dashboard

ID · cfe8e453-52f6-4e9d-8b72-5c304711274f